Gain Therapeutics Inc (GANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.62 Million) by net assets ($18.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GANX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Gain Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gain Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gain Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyobo With Special Purpose Acq
KQ:205100
|
-0.022x |
|
Panelsan Cati Cephe Sistemleri Sanayi ve Ticaret AS
IS:PNLSN
|
0.023x |
|
DOMESCO Medical Import Export JSC
VN:DMC
|
0.001x |
|
United U Li Corporation Bhd
KLSE:7133
|
0.045x |
|
Woorison F&G Co. Ltd
KQ:073560
|
0.033x |
|
Actic Group AB
ST:ATIC
|
0.198x |
|
Airtasker Ltd
AU:ART
|
-0.050x |
|
Top High Image
TWO:3284
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Gain Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Gain Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Gain Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.56 Million | $-18.47 Million | -0.995x | +61.32% |
| 2024-12-31 | $7.34 Million | $-18.87 Million | -2.572x | -71.45% |
| 2023-12-31 | $12.58 Million | $-18.87 Million | -1.500x | -92.74% |
| 2022-12-31 | $18.88 Million | $-14.69 Million | -0.778x | -119.12% |
| 2021-12-31 | $34.82 Million | $-12.37 Million | -0.355x | +32.02% |
| 2020-12-31 | $6.20 Million | $-3.24 Million | -0.522x | -112.58% |
| 2019-12-31 | $-449.86K | $-1.87 Million | 4.154x | +430.50% |
| 2018-12-31 | $-950.91K | $-744.51K | 0.783x | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more